Antibody‐based profiling of cerebrospinal fluid within multiple sclerosis

Antibody suspension bead arrays have proven to enable multiplexed and high‐throughput protein profiling in unfractionated plasma and serum samples through a direct labeling approach. We here describe the development and application of an assay for protein profiling of cerebrospinal fluid (CSF). While setting up the assay, systematic intensity differences between sample groups were observed that reflected inherent sample specific total protein amounts. Supplementing the labeling reaction with BSA and IgG diminished these differences without impairing the apparent sensitivity of the assay. We also assessed the effects of heat treatment on the analysis of CSF proteins and applied the assay to profile 43 selected proteins by 101 antibodies in 339 CSF samples from a multiple sclerosis (MS) cohort. Two proteins, GAP43 and SERPINA3 were found to have a discriminating potential with altered intensity levels between sample groups. GAP43 was detected at significantly lower levels in secondary progressive MS compared to early stages of MS and the control group of other neurological diseases. SERPINA3 instead was detected at higher levels in all MS patients compared to controls. The developed assay procedure now offers new possibilities for broad‐scale protein profiling of CSF within neurological disorders.

[1]  Gary A Rosenberg,et al.  Neurological Diseases in Relation to the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  S. Davies,et al.  Multiplex array proteomics detects increased MMP-8 in CSF after spinal cord injury , 2012, Journal of Neuroinflammation.

[3]  Ulf Landegren,et al.  Opportunities for sensitive plasma proteome analysis. , 2012, Analytical chemistry.

[4]  Mattias Rantalainen,et al.  Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model , 2011, Proteome Science.

[5]  Peter Nilsson,et al.  Systematic antibody and antigen-based proteomic profiling with microarrays , 2011, Expert review of molecular diagnostics.

[6]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[7]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[8]  T. Joos,et al.  Sequential Multiplex Analyte Capturing for Phosphoprotein Profiling* , 2010, Molecular & Cellular Proteomics.

[9]  H. Grönberg,et al.  Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays* , 2010, Molecular & Cellular Proteomics.

[10]  T. Olsson,et al.  Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. , 2010, Journal of proteomics.

[11]  M. Mehling,et al.  A modern approach to CSF analysis: Pathophysiology, clinical application, proof of concept and laboratory reporting , 2009, Clinical Neurology and Neurosurgery.

[12]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[13]  Philippe Marin,et al.  Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. , 2008, Journal of proteome research.

[14]  M. Uhlén,et al.  Antibody suspension bead arrays within serum proteomics. , 2008, Journal of proteome research.

[15]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[16]  D. Thurman,et al.  How common are the “common” neurologic disorders? , 2007, Neurology.

[17]  F. Barkhof,et al.  Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis , 2006, Neuropathology and applied neurobiology.

[18]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[19]  J. Granger,et al.  Albumin depletion of human plasma also removes low abundance proteins including the cytokines , 2005, Proteomics.

[20]  Claudio Franceschi,et al.  Innate immunity and inflammation in ageing: a key for understanding age-related diseases , 2005, Immunity & Ageing.

[21]  Mia Hubert,et al.  ROBPCA: A New Approach to Robust Principal Component Analysis , 2005, Technometrics.

[22]  Jean-Paul Noben,et al.  Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients , 2004, Proteomics.

[23]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[24]  W. Gispen,et al.  B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system , 1997, Progress in Neurobiology.

[25]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[26]  小森 美華,et al.  Proteomic pattern analysis discriminates among multiple sclerosis-related disorders , 2012 .